MedTrace Logo

Lung Health Study II

NCT00000569 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1116

Last updated 2019-11-01

No results posted yet for this study

Summary

To determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo.

Conditions

Interventions

DRUG

triamcinolone

1200 micrograms of triamcinolone in daily divided doses

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • John Connett · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-09-30
Primary Completion
1999-05-31
Completion
1999-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000569 on ClinicalTrials.gov